Uncategorized
Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Aliment Pharmacol Ther. 49(4):408–18. February 2019.
Midazolam dose optimization in critically ill pediatric patients with acute respiratory failure: A population pharmacokinetic-pharmacogenomic study
Zuppa AF, Conrado DJ, Zane NR, Curley MAQ, Bradfield J, Hakonarson H, Gastonguay MS, Moorthy G, Prodell J, Gastonguay MR. Crit Care Med [Internet]. 21 Jan 2019. DOI: 10.1097/CCM.0000000000003638
Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics.
D’Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. J Pharmacokinet Pharmacodyn. 39(1):3. February 2012.
A population pharmacokinetic model of tacrolimus in pediatric liver transplant recipients
Cirrincione-Dall G, Gastonguay MR, Knebel W, Bergsma T, Zhang AY, Patel D, Barrett JS, van Schaik R, Soldin OP, Soldin SJ, Nulmin I, Koren G, de Wildt SN. Presented at ACOP; April 2011; San Diego, CA.
A time to event approach for standard of care meta-analysis in HCV trials
Polhamus D, Baron KT, Purohit VS, Ravva P, Rogers JA, Gastonguay MR. Presented at ACOP; April 2011; San Diego, CA.
Evaluation of rapid and sustained population viral response rates predicted under hepatitis C viral dynamic models
Baron K, Ravva P, Purohit V, Riggs MM, Gastonguay MR. Presented at ACOP; April 2011; San Diego, CA.
Combining summary-level and patient-level data for longitudinal dose-response models: why and how
Rogers JA. Presented at ACOP; April 2011; San Diego, CA.
Application of a multiscale physiologically-based bone and calcium systems model to guide the development of GnRH receptor modulators for the management of endometriosis
Riggs MM, Bennetts M, Martin SW, Van Der Graaf PH. Presented at ACOP; April 2011; San Diego, CA.